New eczema pill shows promise in major trial
NCT ID NCT07180511
First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 23 times
Summary
This study tests an experimental tablet called QY201 for adults with moderate to severe atopic dermatitis (eczema). About 460 participants will take either QY201 or a placebo daily for 16 weeks. The goal is to see if the drug can significantly clear skin and reduce itch, with a focus on safety and long-term control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
EnitiateBioPharma
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.